Skip to main content
46°
Light Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relief Therapeutics Hldg Ag
(OP:
RLFTF
)
5.525
-0.025 (-0.45%)
Streaming Delayed Price
Updated: 2:07 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg Ag
< Previous
1
2
3
4
5
6
7
Next >
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
January 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 03, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
December 30, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
December 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
December 16, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed a Registration Statement on Form 20-F...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
December 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQBRLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
December 14, 2021
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
December 10, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Announces Executive Changes
November 30, 2021
- Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD - Jeremy Meinen promoted to Chief Accounting Officer - Marco Marotta promoted to Chief Business...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
November 29, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
November 24, 2021
Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied...
Via
Benzinga
Exposures
COVID-19
Product Safety
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the "...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
COVID-19
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Therapeutics Launches Level 1 ADR Program in the United States
November 18, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
November 12, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 12, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
November 11, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 11, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
November 09, 2021
- Anthony M. Kim Appointed Senior Vice President and Head of U.S. Commercial Operations - Seasoned Biotech Executive Brings Vast U.S. Commercial Launch Experience to Relief - European and United...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
November 05, 2021
The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil). The Company is developing...
Via
Benzinga
Exposures
COVID-19
Product Safety
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
November 05, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), announced today that it has taken the first steps to establish a Level 1 American...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
November 03, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 3, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
October 27, 2021
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of...
Via
Benzinga
Exposures
COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
October 27, 2021
Results Confirm the Safety and Tolerability of Sentinox and Suggest It Could Be Effective in Reducing Time to Negativization in SARS-CoV-2 Infected Patients GENEVA, SWITZERLAND / ACCESSWIRE / October...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
October 20, 2021
A Prospective Series on Wound Bed Preparation with Nexodyn(R) AOS and Standard of Care and a 32-Week Follow-Up Study Published in the Peer Reviewed Journal of Wound Care GENEVA, SWITZERLAND /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Why NRx Pharmaceuticals Stock Is Tumbling Today
October 15, 2021
The drugmaker is being sued by Relief Therapeutics.
Via
The Motley Fool
Topics
Lawsuit
Exposures
Financial
Legal
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
October 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
October 13, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / October 13, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
October 06, 2021
Lawsuit alleges multiple breaches of Collaboration Agreement GENEVA, SWITZERLAND / ACCESSWIRE / October 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), today announced that...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
October 06, 2021
The FDA has accepted for review Acer Therapeutics Inc (NASDAQ: ACER) and its partner, Relief Therapeutics Holding SA's (OTC: RLFTF) marketing...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.